---
title: "Callan JMB Supports U.S. Scale-Up of Multi-Indication Immune Platform with Phase 2b/3 Advancement | CJMB Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280793955.md"
description: "Callan JMB Supports U.S. Scale-Up of Multi-Indication Immune Platform with Phase 2b/3 Advancement | CJMB Stock News"
datetime: "2026-03-27T04:45:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280793955.md)
  - [en](https://longbridge.com/en/news/280793955.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280793955.md)
---

# Callan JMB Supports U.S. Scale-Up of Multi-Indication Immune Platform with Phase 2b/3 Advancement | CJMB Stock News

Callan JMB Supports U.S. Scale-Up of Multi-Indication Immune Platform with Phase 2b/3 Advancement | CJMB Stock News

### Related Stocks

- [CJMB.US](https://longbridge.com/en/quote/CJMB.US.md)

## Related News & Research

- [ENHANCED PROVIDES CLINICAL TRIAL UPDATE - FIRST OF ITS KIND STUDY CONTINUES WITH ATHLETES HEALTHY & SAFE TO COMPETE | ENHA Stock News](https://longbridge.com/en/news/287124700.md)
- [How Chubb’s (CB) New Canada Cancer Coverage Launch Could Reframe Its Health Benefits Strategy](https://longbridge.com/en/news/286787301.md)
- [Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock.](https://longbridge.com/en/news/286811938.md)
- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [Tiziana Releases Positive Update For Intranasal Foralumab In Treating Multiple Sclerosis](https://longbridge.com/en/news/287092449.md)